6492 Stock Overview A drug development company, engages in the development of new drugs and targeted agents. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Senhwa Biosciences, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Senhwa Biosciences Historical stock prices Current Share Price NT$42.90 52 Week High NT$64.50 52 Week Low NT$40.35 Beta 1.01 1 Month Change -5.19% 3 Month Change -18.13% 1 Year Change -14.20% 3 Year Change -61.70% 5 Year Change -32.23% Change since IPO -58.75%
Recent News & Updates
Senhwa Biosciences, Inc. Announces Retirement of Jin-Ding Huang as General Manager Jan 02
New minor risk - Share price stability Dec 03
Third quarter 2024 earnings released: NT$0.91 loss per share (vs NT$0.84 loss in 3Q 2023) Nov 17
Senhwa Biosciences Announces First Patient Dosed in the Phase I/Ii Study of Silmitasertib in Children and Young Adults with Relapsed Refractory Solid Tumors Nov 07
Senhwa Biosciences, Inc. Announces US FDA Issues Study May Proceed Letter for the Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors, Sponsored by the Us National Cancer Institute Oct 14
Senhwa Biosciences, Inc. Announces IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors Sponsored by NCI Sep 18 See more updates
Senhwa Biosciences, Inc. Announces Retirement of Jin-Ding Huang as General Manager Jan 02
New minor risk - Share price stability Dec 03
Third quarter 2024 earnings released: NT$0.91 loss per share (vs NT$0.84 loss in 3Q 2023) Nov 17
Senhwa Biosciences Announces First Patient Dosed in the Phase I/Ii Study of Silmitasertib in Children and Young Adults with Relapsed Refractory Solid Tumors Nov 07
Senhwa Biosciences, Inc. Announces US FDA Issues Study May Proceed Letter for the Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors, Sponsored by the Us National Cancer Institute Oct 14
Senhwa Biosciences, Inc. Announces IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors Sponsored by NCI Sep 18
US FDA Grants RPD Designation to Senhwa Biosciences Silmitasertib for Pediatric Neuroblastoma Sep 13
Senhwa Biosciences, Inc. Announces Phase Ib Expansion Study Abstract of Cx-5461 in Solid Tumours and Brca2 And/Or Palb2 Mutations Sep 10 Senhwa Biosciences, Inc. Announces Promotion of Sarah Chang as Executive Vice President, Effective August 9, 2024 Aug 10
Senhwa Biosciences, Inc. Receives US FDA Study May Proceed Letter for the Phase I/II Study of Silmitasertib (CX-4945) in Combination with Chemotherapy in Children and Young Adults with Relapsed Refractory Solid Tumors Aug 07
Senhwa Biosciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
Senhwa Biosciences Announces IND Submission to US FDA for the Phase I/II Study of Silmitasertib in Children /Dearyoung Adults with Relapsed Refractory Solid Tumors Jul 12
First quarter 2024 earnings released: NT$0.71 loss per share (vs NT$0.82 loss in 1Q 2023) May 19 Senhwa Biosciences, Inc. to Report Q1, 2024 Results on May 13, 2024 May 05
Senhwa Biosciences, Inc., Annual General Meeting, Jun 21, 2024 Mar 29
Senhwa Biosciences Announces First Patient Dosed in the Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection in Taiwan Mar 20
Full year 2023 earnings released: NT$3.32 loss per share (vs NT$3.92 loss in FY 2022) Mar 17
Senhwa Biosciences, Inc. Decides to Early Terminate the Phase II study of Silmitasertib to treat hospitalized patients with COVID-19 Jan 06
Senhwa Biosciences Receives Taiwan FDA IND Approval for Phase Ii Study of Silmitasertib in Patients with Community-Acquired Pneumonia (Cap) Associated with Viral Infection Dec 26
Third quarter 2023 earnings released: NT$0.84 loss per share (vs NT$0.93 loss in 3Q 2022) Nov 14
Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19 Nov 10
New minor risk - Share price stability Oct 26
Senhwa Biosciences Announces Investigational New Drug Submission to U.S. Food and Drug Administration for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection Oct 20
First half 2023 earnings released: NT$1.54 loss per share (vs NT$1.96 loss in 1H 2022) Aug 16
Less than half of directors are independent Jul 25
Third quarter 2022 earnings released: NT$0.93 loss per share (vs NT$0.97 loss in 3Q 2021) Nov 16
Third quarter 2022 earnings released: NT$0.93 loss per share (vs NT$0.97 loss in 3Q 2021) Nov 13
Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer Nov 01
First half 2022 earnings released: NT$1.96 loss per share (vs NT$1.78 loss in 1H 2021) Aug 15
Senhwa Biosciences, Inc. Pindnarulex in Combination Study with Pfizer's Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC Jun 07
No longer forecast to breakeven May 25
First quarter 2022 earnings: EPS and revenues miss analyst expectations May 17
Price target decreased to NT$143 Apr 27
Less than half of directors are independent Apr 27
Senhwa Biosciences, Inc. Presents Positive Initial Data from Phase 1 Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma at 2022 AAD Annual Meeting Mar 29
Forecast breakeven date pushed back to 2022 Mar 29
Less than half of directors are independent Mar 17
Full year 2021 earnings: EPS and revenues miss analyst expectations Mar 13
Senhwa Biosciences, Inc. Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and Other HR Gene Mutations Jan 26
Us Food and Drug Administration Grants Orphan Drug Designation to Senhwa Biosciences, Inc. for Silmitasertib, A Highly Selective Inhibitor of Casein Kinase 2 (Ck2) Jan 22
Third quarter 2021 earnings released: NT$0.97 loss per share (vs NT$1.53 loss in 3Q 2020) Nov 15
Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference Sep 29
Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Phase 1B Expansion Study of Pidnarulex to Treat Solid Tumors with Specific Homologous Recombination Gene Mutations Sep 11
Senhwa Biosciences Announces Dose Escalation Initiation of the Phase I Trial of Pidnarulex as a Treatment for Advanced Hematological Malignancies Aug 26
Senhwa's Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Recurrent Sonic Hedgehog Driven Medulloblastoma Aug 19
Senhwa Announces Ind Submission to India's Cdsco of A Phase II Clinical Study for Silmitasertib as A Potential Covid-19 Treatment Jun 24
First quarter 2021 earnings released: NT$1.02 loss per share (vs NT$1.13 loss in 1Q 2020) May 16
Full year 2020 earnings released: NT$4.49 loss per share (vs NT$5.26 loss in FY 2019) Mar 27
Analysts Are Optimistic We'll See A Profit From Senhwa Biosciences, Inc. (GTSM:6492) Mar 18
New 90-day low: NT$162 Mar 09
Does This Valuation Of Senhwa Biosciences, Inc. (GTSM:6492) Imply Investors Are Overpaying? Jan 19
New 90-day low: NT$172 Jan 19
Senhwa Biosciences Presents Positive Cholangiocarcinoma Data Jan 16
Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19 Dec 04
Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations Nov 26
Earnings beat expectations Nov 14
Third quarter 2020 earnings released: NT$1.52 loss per share Nov 14
CARE GA Receives Study May Proceed Letter from US FDA to Initiate Phase II Clinical Trial of Senhwa's Silmitasertib in COVID-19 Patients Nov 07
Senhwa Announces Multiple INDApplication Submissions to U.S. FDA for Silmitasertib as A Potential Treatment for COVID-19 Nov 03
New 90-day high - NT$181 Sep 01
First half earnings released Aug 15
New 90-day high - NT$180 Aug 10 Shareholder Returns 6492 TW Biotechs TW Market 7D -2.6% -0.6% -1.8% 1Y -14.2% 4.3% 27.9%
See full shareholder returns
Return vs Industry: 6492 underperformed the TW Biotechs industry which returned 4.6% over the past year.
Return vs Market: 6492 underperformed the TW Market which returned 28.8% over the past year.
Price Volatility Is 6492's price volatile compared to industry and market? 6492 volatility 6492 Average Weekly Movement 4.5% Biotechs Industry Average Movement 4.5% Market Average Movement 4.4% 10% most volatile stocks in TW Market 7.8% 10% least volatile stocks in TW Market 2.1%
Stable Share Price: 6492 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6492's weekly volatility (5%) has been stable over the past year.
About the Company Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is in a phase Ib expansion study of CX-5461 in patients with solid tumors and BRCA2 and /or PALB2 mutation; and CX-5461, which is in Phase I trial of pidnarulex and talazoparib in patients with metastatic castration resistant prostate cancer. It is also developing CX-4945-CCA that is in phase I/II clinical trial in combination with gemcitabine for the treatment of patients with cholangiocarcinoma; CX-4945-BCC, which is in phase I, multi-center, open-label, treatment duration increment, expansion, safety, and pharmacodynamic study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma; and CX-4945-MB, a pediatric brain tumor consortium that is in phase I/II and surgical study of CX-4945 in patients with recurrent SHH medulloblastoma.
Show more Senhwa Biosciences, Inc. Fundamentals Summary How do Senhwa Biosciences's earnings and revenue compare to its market cap? 6492 fundamental statistics Market cap NT$3.83b Earnings (TTM ) -NT$297.21m Revenue (TTM ) NT$1.00m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 6492 income statement (TTM ) Revenue NT$1.00m Cost of Revenue NT$488.00k Gross Profit NT$512.00k Other Expenses NT$297.72m Earnings -NT$297.21m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -3.33 Gross Margin 51.20% Net Profit Margin -29,720.70% Debt/Equity Ratio 0%
How did 6492 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 05:18 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Senhwa Biosciences, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Yenya Kuo Capital Securities Corporation Jane Jiang Yuanta Research
Show 0 more analysts 
